| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Ozanimod | Ozanimod (R)-enantiomer | VE009167 | View CAS 1306760-86-0 |
| Ozanimod | Ozanimod Alcohol Impurity | VE009169 | View CAS 1201447-05-3 |
| Ozanimod | Ozanimod Metabolite | VE009168 | View CAS 2251699-84-8 |
| Ozanimod | Ozanimod N-Formyl Impurity | VE009170 | View |
| Ozanimod | R-Ozanimod HCl | VE0011246 | View CAS 1306760-85-9 |
| Catalogue No. | VE009169 |
| CAS No. | 1201447-05-3 |
| Molecular Formula | C21H19N3O3 |
| Molecular Weight | 361.39 g/mol |
| Parent drug | Ozanimod |
| IUPAC Name | 5-(3-(1-Hydroxy-2, 3-dihydro-1H-inden-4-yl)-1, 2, 4-oxadiazol-5-yl)-2-isopropoxybenzonitrile |
| Synonyms | Des((2-hydroxyethyl)amino) 1-Hydroxy Ozanimod |
| References | Sci-Hub, Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. The Lancet Neurology, 10.1016/s1474-4422(19)30239-x. (2019). Retrieved June 13, 2022, from Sci-hub.se website: https://sci-hub.se/https://doi.org/10.1016/S1474-4422(19)30239-X |
| Status | In-stock |
| ListName | Ozanimod Alcohol Impurity |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
